Vetr upgraded shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) from a buy rating to a strong-buy rating in a research note released on Wednesday. They currently have $475.44 price objective on the biopharmaceutical company’s stock.
Other research analysts also recently issued research reports about the company. Evercore ISI set a $421.00 price objective on Regeneron Pharmaceuticals and gave the stock a hold rating in a report on Sunday, January 8th. Leerink Swann set a $448.00 price objective on Regeneron Pharmaceuticals and gave the stock a buy rating in a report on Saturday, February 11th. Chardan Capital raised Regeneron Pharmaceuticals from a sell rating to a neutral rating and upped their price objective for the stock from $300.00 to $350.00 in a report on Monday, December 12th. BTIG Research reaffirmed a neutral rating on shares of Regeneron Pharmaceuticals in a report on Thursday, November 17th. Finally, Wells Fargo & Co reaffirmed a market perform rating on shares of Regeneron Pharmaceuticals in a report on Tuesday, January 10th. Fourteen analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. Regeneron Pharmaceuticals has an average rating of Hold and an average price target of $434.97.
Regeneron Pharmaceuticals (NASDAQ:REGN) opened at 380.00 on Wednesday. The stock’s 50 day moving average price is $371.86 and its 200-day moving average price is $379.60. The stock has a market cap of $40.08 billion, a P/E ratio of 49.36 and a beta of 1.44. Regeneron Pharmaceuticals has a one year low of $325.35 and a one year high of $452.96.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, February 9th. The biopharmaceutical company reported $3.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.03 by $0.01. Regeneron Pharmaceuticals had a return on equity of 22.51% and a net margin of 18.10%. The firm had revenue of $1.23 billion for the quarter, compared to the consensus estimate of $1.30 billion. During the same quarter in the prior year, the business earned $2.83 EPS. The business’s revenue for the quarter was up 11.7% compared to the same quarter last year. On average, analysts predict that Regeneron Pharmaceuticals will post $12.95 earnings per share for the current year.
Your IP Address:
In other news, major shareholder Sanofi bought 87,298 shares of the stock in a transaction on Wednesday, January 11th. The stock was purchased at an average price of $369.71 per share, for a total transaction of $32,274,943.58. The transaction was disclosed in a filing with the SEC, which is available at this link. 10.40% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently added to or reduced their stakes in REGN. Norges Bank purchased a new position in Regeneron Pharmaceuticals during the fourth quarter worth about $291,560,000. WFG Advisors LP boosted its position in Regeneron Pharmaceuticals by 12,358.3% in the fourth quarter. WFG Advisors LP now owns 7,475 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 7,415 shares during the period. I.G. Investment Management LTD. boosted its position in Regeneron Pharmaceuticals by 560.4% in the fourth quarter. I.G. Investment Management LTD. now owns 5,600 shares of the biopharmaceutical company’s stock worth $2,056,000 after buying an additional 4,752 shares during the period. Thrivent Financial for Lutherans boosted its position in Regeneron Pharmaceuticals by 6.5% in the fourth quarter. Thrivent Financial for Lutherans now owns 2,620 shares of the biopharmaceutical company’s stock worth $962,000 after buying an additional 160 shares during the period. Finally, IFM Investors Pty Ltd purchased a new position in Regeneron Pharmaceuticals during the fourth quarter worth about $373,000. Hedge funds and other institutional investors own 68.83% of the company’s stock.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
To view Vetr’s full report, visit Vetr’s official website.
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/regeneron-pharmaceuticals-inc-regn-raised-to-strong-buy-at-vetr-inc/1708947.html
Receive News & Ratings for Regeneron Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.